Carcinogenicity risk associated with tacrolimus use in kidney transplant recipients: a systematic review and meta-analysis.

ABSTRACT:

Background

Currently, tacrolimus is the preferred anti-rejection therapy for kidney transplant recipients due to its greater protection against acute rejections compared to cyclosporin A (CsA). Despite the advantages of kidney transplantation, it has been associated with an increased incidence of de novo malignancies. Furthermore, a systematic review in 2005 revealed no statistical difference in tumorigenicity between tacrolimus and CsA. This report provides an up to date systematic review and evaluation of all relevant studies in the literature to determine the risk of malignancy in kidney transplant recipients exposed to tacrolimus.

Methods

A systematic literature search was performed using the Medline (PubMed and Ovid), Embase, Clinical Trials, and Cochrane databas

SUBMITTER: Wang L 

PROVIDER: S-EPMC8984978 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature